SECRET-ITN

Exploring the SECRET ory pathway regulation and its contribution to cancer by providing a highly qualified platform for European research training of bright young scientists, with the aim of defining secretory pathway-linked candidate biomarker genes suitable for cancer diagnosis and prognosis... In 2018, 4.2 million new cancer cases were diagnosed in Europe with breast and colorectal cancer (BC and CRC) representing the most frequent cancers. Despite strong efforts, BC and CRC still account for 7% and 13%, respectively, of all deaths from cancer in Europe in both sexes. In the case of triple-negative BC (TNBC, lacking hormone and HER2 receptor expression) accounting for 15% of all BC cases, there are no targeted therapies available and non-selective chemotherapy is the only treatment option.

Primary location: Stuttgart Germany